Literature DB >> 15598974

Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.

Karin F K Ejendal1, Christine A Hrycyna.   

Abstract

Several ATP-binding cassette (ABC) transporters can confer multidrug resistance to cancer cells by functioning as energy-dependent efflux pumps. The half-transporter ABCG2 and the widely studied P-glycoprotein (P-gp) are two ABC transporters that, when overexpressed, are capable of extruding a variety of structurally unrelated chemotherapy agents from cells. In this study, we demonstrate that human ABCG2 and P-glycoprotein, despite overlapping substrate specificities, differ in sensitivity to the immunomodulator cyclosporin A. In this study, we used human ABCG2 and human P-gp, each expressed separately in drug-selected MCF-7 sublines and transiently transfected HeLa cells. By flow cytometric analysis using the fluorescent substrates rhodamine 123 and mitoxantrone, we showed that cyclosporin A inhibits P-gp function at low micromolar concentrations, whereas ABCG2 function was unaffected. Furthermore, P-gp, but not ABCG2, was able to transport [3H]cyclosporin A directly in intact cells. We also demonstrated, for the first time, that [125I]iodoarylazidoprazosin, a photoaffinity analog of the substrate prazosin, labels multiple variants of ABCG2 specifically and that this labeling, although competed by some ABCG2 substrates, is unaffected by cyclosporin A. These labeling data also suggest the presence of multiple drug binding sites in ABCG2. In addition, cyclosporin A had no effect on the basal or prazosin-stimulated ATPase activity of ABCG2, whereas both the basal and verapamil-stimulated ATPase activities of P-gp were inhibited markedly. Together, our results suggest that cyclosporin A is neither a substrate nor an inhibitor of the human ABCG2 transporter, under the conditions and concentrations examined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15598974     DOI: 10.1124/mol.104.001701

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  17 in total

1.  Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis.

Authors:  Hazem E Hassan; Alan L Myers; Insong J Lee; Hegang Chen; Andrew Coop; Natalie D Eddington
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

2.  The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.

Authors:  Karin F K Ejendal; Ndeye Khady Diop; Linda C Schweiger; Christine A Hrycyna
Journal:  Protein Sci       Date:  2006-07       Impact factor: 6.725

3.  Evolutionarily Conserved Roles for Blood-Brain Barrier Xenobiotic Transporters in Endogenous Steroid Partitioning and Behavior.

Authors:  Samantha J Hindle; Roeben N Munji; Elena Dolghih; Garrett Gaskins; Souvinh Orng; Hiroshi Ishimoto; Allison Soung; Michael DeSalvo; Toshihiro Kitamoto; Michael J Keiser; Matthew P Jacobson; Richard Daneman; Roland J Bainton
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

4.  Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.

Authors:  Pornngarm Limtrakul; Wanida Chearwae; Suneet Shukla; Chada Phisalphong; Suresh V Ambudkar
Journal:  Mol Cell Biochem       Date:  2006-09-08       Impact factor: 3.396

5.  In vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.

Authors:  Hong-May Sim; Chung-Pu Wu; Suresh V Ambudkar; Mei-Lin Go
Journal:  Biochem Pharmacol       Date:  2011-08-17       Impact factor: 5.858

6.  Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).

Authors:  Andaleeb Sajid; Natarajan Raju; Sabrina Lusvarghi; Shahrooz Vahedi; Rolf E Swenson; Suresh V Ambudkar
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

7.  Substrate-dependent effects of human ABCB1 coding polymorphisms.

Authors:  Jason M Gow; Laura M Hodges; Leslie W Chinn; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-02-20       Impact factor: 4.030

8.  Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

Authors:  Nagdeep Giri; Sagar Agarwal; Naveed Shaik; Guoyu Pan; Ying Chen; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

9.  Overlapping substrate and inhibitor specificity of human and murine ABCG2.

Authors:  Joshua Bakhsheshian; Matthew D Hall; Robert W Robey; Michelle A Herrmann; Jin-Qiu Chen; Susan E Bates; Michael M Gottesman
Journal:  Drug Metab Dispos       Date:  2013-07-18       Impact factor: 3.922

Review 10.  Myopathy with statin-fibrate combination therapy: clinical considerations.

Authors:  Terry A Jacobson
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.